NCT02338674View on ClinicalTrials.gov

TDF and LdT in Immune-tolerant CHB Patients Awaiting Assisted Reproduction

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

121

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

October 31, 2016

Study Completion Date

October 31, 2017

Conditions
Hepatitis B, Chronic
Interventions
DRUG

Tenofovir and telbivudine

tenofovir and telbivudine administered at least 48 weeks

DRUG

Tenofovir

tenofovir administered at least 48 weeks

Trial Locations (1)

350025

Fuzhou General Hospital, Xiamen Univ, Fuzhou

All Listed Sponsors
lead

Fuzhou General Hospital

OTHER

NCT02338674 - TDF and LdT in Immune-tolerant CHB Patients Awaiting Assisted Reproduction | Biotech Hunter | Biotech Hunter